What they were paid
Intra-Cellular Therapies Director Compensation Table · the one fiscal year held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2023 | $73,393 | $99,959 | $299,985 | — | $473,337 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Intra-Cellular Therapies, Inc. DEF 14A filed April 29, 2024, accession 0001628280-24-018986, and prior-year filings. Open the filing on EDGAR.
How this board is paid
company policy · FY2023Intra-Cellular Therapies pays directors a $50,000 cash retainer and $675,000 in RSUs/Options.
Committees
FY2023 · as the proxy prints themCompensation (Chair)
The rest of the Intra-Cellular Therapies board
FY2023 · as the company reported each| Director | Role | FY2023 total |
|---|---|---|
| E. Rene Salas | Independent Director | $461,301 |
| Robert L. Van Nostrand | Lead Independent Director | $507,583 |
| Rory B. Riggs | Independent Director | $470,507 |
| Sharon Mates | Chair of the Board | $0 |
The full Intra-Cellular Therapies compensation record
free company briefThis page is one director within Intra-Cellular Therapies's record. The company brief lists every named executive and director, each linking to their own page.
Velarion Pro: every company page, peer tools and exports, one seat